Phase II Study of Weekly Oxaliplatin With Continous Infusion Fluorouracil And Concurrent Radiation for Treatment of Localised Oesophageal Carcinoma

Oxaliplatin is designated chemically as [SP-4-2]-(1R,2R)-(cyclohexane-1,2-diamine-k2N,Nÿ¿ÿ´ (oxalato(2-)-k2O1,O2]platinum (II) given by intravenous infusion. This is a single arm open label Phase II study of chemo-radiation of localised oesophageal cancer with Oxaliplatin, continuous infusion fluorouracil and radiation. The duration of the study participation will include for each patient a 1 week inclusion and treatment planning period, followed by a 6 week treatment period, followed by a minimum of 1 week follow-up for chemotherapy related toxicities after the completion of the study treatment. In addition all patients will be followed for radiation toxicity and disease status for 2 years after the completion of the study treatment. Treatment Regimen: *5-fluorouracil via continuous intravenous infusion at the dose of 225mg/m2/day commencing on first day of radiation and continuing until delivery of last radiation fraction. *Oxaliplatin given by 2-hour intravenous infusion at a dose of 60mg/m2 weekly commencing immediately prior to the commencement of 5-fluorouracil Radiation-Standard total 54 to 60 Gy, given daily apart from weekends and public holidays